Reporting of HRQoL results from the PALOMA-2 trial: Relevant data are still missing
- PMID: 29873692
- PMCID: PMC6096735
- DOI: 10.1093/annonc/mdy204
Reporting of HRQoL results from the PALOMA-2 trial: Relevant data are still missing
Comment in
-
Reply to the letter to the editor 'Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses' by Kaiser et al.Ann Oncol. 2018 Aug 1;29(8):1878. doi: 10.1093/annonc/mdy206. Ann Oncol. 2018. PMID: 29873677 No abstract available.
Comment on
-
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012. Ann Oncol. 2018. PMID: 29360932 Free PMC article. Clinical Trial.
References
-
- Finn RS, Martin M, Rugo HS. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375(20): 1925–1963. - PubMed
-
- Pfizer Pharma GmbH. Dossier zur Nutzenbewertung gemäss § 35a SGB V: Palbociclib (Ibrance®); Modul 4A: Medizinischer Nutzen und medizinischer Zusatznutzen, Patientengruppen mit therapeutisch bedeutsamem Zusatznutzen. Stand: 22.11.2016. https://www.g-ba.de/downloads/92-975-1744/2016-11-22_Palbociclib_Modul4A... (20 March 2018, date last accessed).
-
- Institute for Quality and Efficiency in Health Care. Palbociclib (breast cancer) – benefit assessment according to §35a Social Code Book V. Published online 1 March 2017. https://www.iqwig.de/en/projects-results/projects/drug-assessment/a16-74... (20 March 2018, date last accessed).
-
- FACIT. FACT-B Scoring & Interpretation Materials. http://www.facit.org/FACITOrg/Questionnaires (20 March 2018, date last accessed).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
